David R Serwanski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
David R Serwanski has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Debayon Paul
Department of Cell Biology, Blood–brain Barrier Laboratory, 263 Farmington Ave., Farmington CT 06030, USA
1 shared publication - Evan R. Jellison
Department of Immunology, University of Connecticut School of Medicine (UConn Health), Farmington, USA
1 shared publication - Joel S. Pachter
University of Connecticut Health Center
1 shared publication - Nancy H. Ruddle
Yale School of Public Health
1 shared publication - Shujun Ge
Blood-Brain Laboratory, UConn Health, USA; Department of Immunology, UConn Health, USA
1 shared publication - Yen Lemire
Department of Cell Biology, Blood–brain Barrier Laboratory, 263 Farmington Ave., Farmington CT 06030, USA
1 shared publication
Latest Publications
- Open Access
- 21 January 2014
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 11 (1) , 10
Cell-selective knockout and 3D confocal image analysis reveals separate roles for astrocyte-and endothelial-derived CCL2 in neuroinflammation
Expression of chemokine CCL2 in the normal central nervous system (CNS) is nearly undetectable, but is significantly upregulated and drives neuroinflammation during experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis which is considered a contributing factor in the human disease. As astrocytes and brain microvascular endothelial cells (BMEC) forming the blood–brain barrier (BBB) are sources of CCL2 in EAE and other neuroinflammatory conditions, it is unclear if one or both CCL2 pools are critical to disease and by what mechanism(s).
- 21 January 2014
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 11 (1) , 10
Open AccessCell-selective knockout and 3D confocal image analysis reveals separate roles for astrocyte-and endothelial-derived CCL2 in neuroinflammation
Expression of chemokine CCL2 in the normal central nervous system (CNS) is nearly undetectable, but is significantly upregulated and drives neuroinflammation during experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis which is considered a contributing factor in the human disease. As astrocytes and brain microvascular endothelial cells (BMEC) forming the blood–brain barrier (BBB) are sources of CCL2 in EAE and other neuroinflammatory conditions, it is unclear if one or both CCL2 pools are critical to disease and by what mechanism(s).